Imdusiran, IMFINZI 50 mg/mL concentrate for solution for infusion. clinical trials

A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection

This study is checking a new medicine called Imdusiran alongside an existing one, Durvalumab (Imfinzi), for people with long-term Hepatitis B. Researchers want to see if this combination is safe, how well people tolerate it, and how it affects the body.